Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Aging (NIA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to investigate the feasibility (safety, adherence) and initial efficacy (physical function and patient reported outcomes) of a multicomponent tele-rehabilitation program during COVID-19 recovery of patients who have been hospitalized due to COVID-19.
The aim of this study is to investigate the feasibility and initial efficacy of a multicomponent tele-rehabilitation program during COVID-19 recovery. The tele-rehabilitation program will include biobehavioral training and high intensity exercise facilitated through an online application ('Platform'). Initial efficacy will be assessed primarily by performance on the 30" Chair Stand Test and secondarily through other physical function tests and patient reported outcome measures.
This study will advance the feasibility of tele-rehabilitation as a more generally useful intervention in patients lacking access (distance, availability, mobility) to standard rehabilitative services and could transform the way in which acute rehabilitation and post-hospital care is delivered for all patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | This group will receive 12 biobehaviorally informed tele-rehabilitation sessions including high-intensity strengthening; sessions will be delivered by a licensed physical therapist. An application ('Platform') will facilitate home exercise program completion outside of the supervised sessions. Other: remote controlled exercise plus home exercise Treatments: strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise |
|
| Control | No Intervention | This group will receive an activity monitor and basic education, but no individualized rehabilitation sessions or biobehavioral training. Other: basic education |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biobehavioral Tele-rehabilitation Sessions | Behavioral | Biobehavioral tele-rehabilitation sessions |
|
| Measure | Description | Time Frame |
|---|---|---|
| Adherence (Primary Feasibility/Safety Outcome) | Feasibility will be measured by program adherence, defined as the number of sessions attended divided by the total number of prescribed sessions (n=12). Individuals will be considered adherent if they attend at least 75% (n=9) of the total sessions. Adherence will be collected in the intervention group only. | 12 weeks |
| Change in 30 Second Chair Stand Test (Primary Efficacy Outcome) | The test uses a standard height chair and requires the participant to stand up and sit down as many times as possible in 30 seconds. More completions indicate better physical function. To facilitate accuracy of the test over video, the participant will be instructed to count out loud each time he/she stands. Further, the test will also be facilitated by the Platform. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| System Usability Scale (SUS) | The SUS is a 10-item survey that uses a 5-point Likert scale (Strongly disagree (1) to Strongly agree (5)). Scores range from 0 to 100 and higher scores indicate better usability. The SUS will be collected in the intervention group only. | 6 weeks (primary end point) |
| Safety Event Count |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kristine Erlandson, MD | University of Colorado, Denver | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Colorado Hospital | Aurora | Colorado | 80045 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36939818 | Derived | Churchill L, Morrow M, Capin JJ, Jolley SE, Hare K, MaWhinney S, Stevens-Lapsley JE, Erlandson KM. Using Wearable Technology to Quantify Physical Activity Recovery: Secondary Report From the AFTER (App-Facilitated Tele-Rehabilitation) Program for COVID-19 Survivors Randomized Study. JMIR Rehabil Assist Technol. 2023 Mar 20;10:e43436. doi: 10.2196/43436. | |
| 35882451 |
Not provided
Not provided
Upon written request of the study team and an established data use agreement (DUA) between the University of Colorado Anschutz Medical Campus (UCD-AMC) and the requestor's institution, we will provide a deidentified dataset including a data dictionary. Deidentification of the datasets will be conducted with respect to HIPAA definitions, with add back of variables that express all dates as number of days since a milestone event, enrollment, and a variable storing just the year. For example, the milestone event would be "Day 0" in this case.
The main study results will be posted in ClinicalTrials.gov and will remain there indefinitely. All other study documents and data will be made available within a reasonable time frame following a valid written request.
Other related study documents will be made available upon reasonable written request
Not provided
5 participants screen failed after enrolling, prior to starting the study.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Intervention | This group will receive 12 biobehaviorally informed tele-rehabilitation sessions including high-intensity strengthening; sessions will be delivered by a licensed physical therapist. An application ('Platform') will facilitate home exercise program completion outside of the supervised sessions. Other: remote controlled exercise plus home exercise Treatments: strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise Biobehavioral Tele-rehabilitation Sessions: Biobehavioral tele-rehabilitation sessions |
| FG001 | Control | This group will receive an activity monitor and basic education, but no individualized rehabilitation sessions or biobehavioral training. Other: basic education |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Demographics data was only reported for participants who completed the Week 6 evaluation.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Intervention | This group will receive 12 biobehaviorally informed tele-rehabilitation sessions including high-intensity strengthening; sessions will be delivered by a licensed physical therapist. An application ('Platform') will facilitate home exercise program completion outside of the supervised sessions. Other: remote controlled exercise plus home exercise Treatments: strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise Biobehavioral Tele-rehabilitation Sessions: Biobehavioral tele-rehabilitation sessions |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Adherence (Primary Feasibility/Safety Outcome) | Feasibility will be measured by program adherence, defined as the number of sessions attended divided by the total number of prescribed sessions (n=12). Individuals will be considered adherent if they attend at least 75% (n=9) of the total sessions. Adherence will be collected in the intervention group only. | Adherence was collected in the intervention group only. | Posted | Mean | 95% Confidence Interval | % of participants meeting adherence | 12 weeks |
|
12 Weeks
All safety events were categorized and counted and falls were graded according to the Falls-Grading Scale.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Intervention | This group will receive 12 biobehaviorally informed tele-rehabilitation sessions including high-intensity strengthening; sessions will be delivered by a licensed physical therapist. An application ('Platform') will facilitate home exercise program completion outside of the supervised sessions. Other: remote controlled exercise plus home exercise Treatments: strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise Biobehavioral Tele-rehabilitation Sessions: Biobehavioral tele-rehabilitation sessions |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hospitalization | General disorders | Non-systematic Assessment | 2 participants were hospitalized for shortness of breath. 1 participant was hospitalized after being found passed out. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Falls | Injury, poisoning and procedural complications | Non-systematic Assessment | Falls were graded according to the Falls-Grading Scale. |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Jennifer Stevens-Lapsley | University of Colorado Denver | 303.724.9170 | PT.studies@cuanschutz.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | May 5, 2022 | Jul 6, 2022 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | May 5, 2022 | Jul 6, 2022 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Safety Event Count is the cumulative number of participants who experienced adverse events and severe adverse events counted from baseline to week 12. Events will be categorized by type. |
| Week 12 |
| Timed Up-and-Go Test (TUG) | The TUG test measures the time it takes for a person to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down. Participants will complete the TUG test twice and the best time will be used. Faster times indicate better physical function and lower risk of falls. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| 4-Stage Balance Test | The 4-stage balance test measures static balance in 4 different positions (narrow base of support, semi-tandem, tandem, and single-leg). The test is facilitated by the Platform; it requires participants to hold each position for up to 10 seconds. If a participant is unable to hold a position for 10 seconds, the next hardest position is not performed. Completing higher levels indicate lesser fall risk and better balance. Total scores range from 0 to 40, with higher scores indicating better outcomes. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| MRC Dyspnea | The MRC dyspnea scale is an interviewer-administered or self-report assessment of the perception of difficulty breathing during five different tasks. Participants respond either yes or no to each task. Score is the sum of the number of Yes answers, 0-5. Higher numbers indicate more difficulty breathing | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| Activities-Specific Balance Confidence (ABC) Scale | The ABC Scale is a 16-item self-report measure of balance confidence in performing activities without losing balance or experiencing a sense of unsteadiness. Score range: 0-100. Higher scores indicate higher confidence in performing activities without losing balance. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| Three-Item Loneliness Scale | This scale has three items and a simplified set of response categories that is designed to measure overall loneliness. Score range: 3-9. Higher scores indicate higher loneliness. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| PROMIS Short Form (SF) v1.0 General Self-Efficacy 4a | The PROMIS Short Form (SF) v1.0 General Self-Efficacy 4a consists of 4 items rated on a 5-point Likert scale (not at all confident (1) to very confident (5)); values range from 4-20. Higher scores indicate higher levels of general self-efficacy. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| PROMIS Short Form (SF) Self-Efficacy for Managing Chronic Conditions | The PROMIS Short Form (SF) Self-Efficacy for Managing Chronic Conditions is an 8-item scale rated on a 5-point Likert scale;values range from 8-32. Higher scores indicate higher levels of self confidence in one's ability to successfully perform specific tasks or behaviors related to one's health in a variety of situations. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| PROMIS Scale v1.2 Global Health: | The PROMIS Scale v1.2 Global Health measures quality of life on two domains: physical and mental health. Raw values for each domain range from 4 - 20; scores are converted to a t-score with a mean of 50 and SD of 10. Higher scores indicate better health. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| Montreal Cognitive Assessment (MoCA)-BLIND | The MoCA-BLIND assesses different cognitive domains: attention, concentration, memory, language, conceptual thinking, calculations, and orientation. The MoCA-BLIND has removed assessments requiring vision, thus can be completed using telehealth or telephone assessments. Score range: 0-22, with 18-22 normal range. | Change from Baseline to week 12 |
| Clinical Frailty Scale | The Clinical Frailty scale is a self-report scale to estimate function. The participant selects perceived level of function prior to and following admission ranging from very active to bedridden/terminal. Score range: 1 (very fit) - 9 (terminally ill), with higher scores indicating higher levels of frailty. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| Average Daily Step Count | Average Daily Step Count per week will be collected via a Fitbit activity monitor. Higher step counts indicate higher level of physical activity. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| Patient Health Questionnaire 8 (PHQ8) | The Patient Health Questionnaire 8 measures severity of depressive symptoms over the past 2 weeks. The 8 item scale is rated on a 4 point scale (not at all to nearly every day). Score range: 0-24. Higher scores indicate more severe depressive symptoms. | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
| Capin JJ, Jolley SE, Morrow M, Connors M, Hare K, MaWhinney S, Nordon-Craft A, Rauzi M, Flynn S, Stevens-Lapsley JE, Erlandson KM. Safety, feasibility and initial efficacy of an app-facilitated telerehabilitation (AFTER) programme for COVID-19 survivors: a pilot randomised study. BMJ Open. 2022 Jul 26;12(7):e061285. doi: 10.1136/bmjopen-2022-061285. |
| BG001 | Control | This group will receive an activity monitor and basic education, but no individualized rehabilitation sessions or biobehavioral training. Other: basic education |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| 30 Second Chair Stand Test | The test uses a standard height chair and requires the participant to stand up and sit down as many times as possible in 30 seconds. More completions indicate better physical function. To facilitate accuracy of the test over video, the participant will be instructed to count out loud each time he/she stands. Further, the test will also be facilitated by the Platform. | Mean | Standard Deviation | Completions |
|
| Timed Up-and-Go Test (TUG) | The TUG test measures the time it takes for a person to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down. Participants will complete the TUG test twice and the best time will be used. Faster times indicate better physical function and lower risk of falls. | Mean | Standard Deviation | seconds |
|
| 4-Stage Balance Test | The 4-stage balance test measures static balance in 4 different positions (narrow base of support, semi-tandem, tandem, and single-leg). The test is facilitated by the Platform; it requires participants to hold each position for up to 10 seconds. If a participant is unable to hold a position for 10 seconds, the next hardest position is not performed. Completing higher levels indicate lesser fall risk and better balance. Total scores range from 0 to 40, with higher scores indicating better outcomes. | Mean | Standard Deviation | scores on a scale |
|
| OG001 | Control | This group will receive an activity monitor and basic education, but no individualized rehabilitation sessions or biobehavioral training. Other: basic education |
|
|
| Primary | Change in 30 Second Chair Stand Test (Primary Efficacy Outcome) | The test uses a standard height chair and requires the participant to stand up and sit down as many times as possible in 30 seconds. More completions indicate better physical function. To facilitate accuracy of the test over video, the participant will be instructed to count out loud each time he/she stands. Further, the test will also be facilitated by the Platform. | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | Completions | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | System Usability Scale (SUS) | The SUS is a 10-item survey that uses a 5-point Likert scale (Strongly disagree (1) to Strongly agree (5)). Scores range from 0 to 100 and higher scores indicate better usability. The SUS will be collected in the intervention group only. | SUS was only collected on Intervention Group | Posted | Median | Full Range | score on a scale | 6 weeks (primary end point) |
|
|
|
| Secondary | Safety Event Count | The Safety Event Count is the cumulative number of participants who experienced adverse events and severe adverse events counted from baseline to week 12. Events will be categorized by type. | Posted | Count of Participants | Participants | Week 12 |
|
|
|
| Secondary | Timed Up-and-Go Test (TUG) | The TUG test measures the time it takes for a person to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down. Participants will complete the TUG test twice and the best time will be used. Faster times indicate better physical function and lower risk of falls. | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | seconds | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | 4-Stage Balance Test | The 4-stage balance test measures static balance in 4 different positions (narrow base of support, semi-tandem, tandem, and single-leg). The test is facilitated by the Platform; it requires participants to hold each position for up to 10 seconds. If a participant is unable to hold a position for 10 seconds, the next hardest position is not performed. Completing higher levels indicate lesser fall risk and better balance. Total scores range from 0 to 40, with higher scores indicating better outcomes. | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | score on a scale | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | MRC Dyspnea | The MRC dyspnea scale is an interviewer-administered or self-report assessment of the perception of difficulty breathing during five different tasks. Participants respond either yes or no to each task. Score is the sum of the number of Yes answers, 0-5. Higher numbers indicate more difficulty breathing | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | score on a scale | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | Activities-Specific Balance Confidence (ABC) Scale | The ABC Scale is a 16-item self-report measure of balance confidence in performing activities without losing balance or experiencing a sense of unsteadiness. Score range: 0-100. Higher scores indicate higher confidence in performing activities without losing balance. | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | score on a scale | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | Three-Item Loneliness Scale | This scale has three items and a simplified set of response categories that is designed to measure overall loneliness. Score range: 3-9. Higher scores indicate higher loneliness. | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | score on a scale | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | PROMIS Short Form (SF) v1.0 General Self-Efficacy 4a | The PROMIS Short Form (SF) v1.0 General Self-Efficacy 4a consists of 4 items rated on a 5-point Likert scale (not at all confident (1) to very confident (5)); values range from 4-20. Higher scores indicate higher levels of general self-efficacy. | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | score on a scale | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | PROMIS Short Form (SF) Self-Efficacy for Managing Chronic Conditions | The PROMIS Short Form (SF) Self-Efficacy for Managing Chronic Conditions is an 8-item scale rated on a 5-point Likert scale;values range from 8-32. Higher scores indicate higher levels of self confidence in one's ability to successfully perform specific tasks or behaviors related to one's health in a variety of situations. | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | score on a scale | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | PROMIS Scale v1.2 Global Health: | The PROMIS Scale v1.2 Global Health measures quality of life on two domains: physical and mental health. Raw values for each domain range from 4 - 20; scores are converted to a t-score with a mean of 50 and SD of 10. Higher scores indicate better health. | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | score on a scale | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | Montreal Cognitive Assessment (MoCA)-BLIND | The MoCA-BLIND assesses different cognitive domains: attention, concentration, memory, language, conceptual thinking, calculations, and orientation. The MoCA-BLIND has removed assessments requiring vision, thus can be completed using telehealth or telephone assessments. Score range: 0-22, with 18-22 normal range. | Posted | Mean | 95% Confidence Interval | score on a scale | Change from Baseline to week 12 |
|
|
|
| Secondary | Clinical Frailty Scale | The Clinical Frailty scale is a self-report scale to estimate function. The participant selects perceived level of function prior to and following admission ranging from very active to bedridden/terminal. Score range: 1 (very fit) - 9 (terminally ill), with higher scores indicating higher levels of frailty. | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | score on a scale | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | Average Daily Step Count | Average Daily Step Count per week will be collected via a Fitbit activity monitor. Higher step counts indicate higher level of physical activity. | One participant in the control group did not complete week 12. | Posted | Mean | 95% Confidence Interval | change in daily step count | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| Secondary | Patient Health Questionnaire 8 (PHQ8) | The Patient Health Questionnaire 8 measures severity of depressive symptoms over the past 2 weeks. The 8 item scale is rated on a 4 point scale (not at all to nearly every day). Score range: 0-24. Higher scores indicate more severe depressive symptoms. | The control group had one participant who did not complete week 12 testing. | Posted | Mean | 95% Confidence Interval | score on a scale | Change from Baseline to 6 weeks (primary end point), persisting at 12 weeks |
|
|
|
| 0 |
| 29 |
| 2 |
| 29 |
| 0 |
| 29 |
| EG001 | Control | This group will receive an activity monitor and basic education, but no individualized rehabilitation sessions or biobehavioral training. Other: basic education | 0 | 15 | 1 | 15 | 6 | 15 |
|
|
Not provided
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|
| Change at Week 12 |
|
|